You are here

FDA Accepts New Drug Application for Zegerid Capsules

SAN DIEGO--(BUSINESS WIRE)--June 28, 2005--Santarus, Inc. (Nasdaq:SNTS), a specialty pharmaceutical company focused on therapies for gastrointestinal diseases and disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company's New Drug Application (NDA) for ZEGERID(R) (omeprazole) Capsules 40 mg and 20 mg. Pursuant to Prescription Drug User Fee Act (PDUFA) guidelines, Santarus expects the FDA will complete its review or otherwise respond to the ZEGERID Capsules NDA by February 26, 2006. Santarus is seeking marketing approval of ZEGERID Capsules as the first immediate-release proton pump inhibitor (PPI) in a capsule formulation for the treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD), erosive esophagitis, duodenal ulcers and gastric ulcers. Capsules are the most widely used dosage form within the PPI class of drugs.

"We believe that GERD patients may find our immediate-release capsules convenient for daily use and, subject to regulatory approval, commercialization of this formulation could broaden ZEGERID usage," said Gerald T. Proehl, president and chief executive officer of Santarus. "Acceptance of our ZEGERID Capsules NDA submission is an important step in reaching our goal to expand the ZEGERID product family. We plan to offer three product formulations of immediate-release ZEGERID, including powder for oral suspension, capsules and chewable tablets."

Santarus is currently marketing ZEGERID Powder for Oral Suspension 40 mg and 20 mg, an immediate-release PPI product which is rapidly absorbed (reaching peak plasma levels in approximately 30 minutes) and provides strong 24-hour acid control with once daily dosing.

In connection with the FDA's acceptance for filing of the ZEGERID Capsules NDA, Santarus provided notice to the NDA holder for Prilosec(R) delayed-release omeprazole capsules and related patent holders that ZEGERID Capsules 40 mg and 20 mg do not infringe the patents listed in the Orange Book for Prilosec or that those patents are invalid.

Source: Santarus, Inc.

Recent Headlines

Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs